anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To monitor the sleeping conditions of a number of persons all together in a centralizing fashion by constituting a sleep monitoring device of a plurality of beds each provided with bedding in which a filtering circuit, an amplifying circuit, a rectifying circuit, an integrating circuit, a comparing circuit, a timer, a judging circuit, and a piezoelectric element are disposed, and a display means for displaying the output signal of each judging circuit via a communicating means. CONSTITUTION:When a piezoelectric element 2 on each bed 1 is deformed by the motion of a user's body on a mattress 3, a voltage is generated from the piezoelectric element 2 by piezoelectric effects. Only frequency components of approximately 1 to 10Hz are allowed to pass through a filtering circuit 4, amplified by an amplifying circuit 5, rectified by a rectifying circuit 6, and integrated by an integrating circuit 7. When an output signal from a comparing circuit 8 is at Hi level a timer 9 starts measuring time and continues to do so. When the time measured by the timer 9 exceeds a predetermined level, a judging circuit 10 judges that the human body on each bed has fallen asleep. Data judged at each bed is integrally displayed in a display 13 via a communicating cable 12.
Free-flowing medicinal and like tablet granulations of substantially uniform size and shape are prepared by suspending small solid particles (e.g. of medicament, sugar "seeds" or particles comprising a medicament and an inert pharmaceutical diluent) in a gas (e.g. air or nitrogen) stream in fluidized bed form, introducing into the gas stream an atomized granulating mixture comprising conventional granulating materials in both solution and suspension and, optionally, a medicament, in a volatile liquid (e.g. water, lower alkanols, acetone or mixtures thereof) and optionally subsequently lubricating the resulting granules by similarly introducing an atomized liquid lubricating composition comprising, for example, conventional liquid lubricants or a solution and/or suspension of conventional solid lubricants in a volatile liquid.  Preferably, the gas stream is directed through one part of the bed at a velocity greater than that through another part, thereby permitting circulation of the particles in the bed.  Specified medicaments are codeine sulphate, ephedrine sulphate, vitamins, e.g. nicotinic acid, ascorbic acid, atropine sulphate, morphine sulphate, pentabarbital sodium, pheno-bartital, sodium chloride, powdered digitalis, sodium salicylate, acetylsalicylic acid, ferrous sulphate, sodium bicarbonate, nicotinic acid, p-aminobenzoic acid, sulphamerazine and quinidine salts.  A suitable apparatus for carrying out the process of the invention is described.
The present disclosure provides crystalline forms of the compound having Formula (I), wherein the crystalline forms are crystalline Forms A to U. The crystalline Forms A to U are characterized by an X-ray powder diffraction (XRPD) pattern. Selected crystalline forms are further characterized by a differential scanning calorimetry (DSC), a thermal gravimetric analysis (TGA), and/or a polarized light microscope (PLM) profile. The present disclosure also provides a substantially amorphous form of the compound having Formula (I), which is prepared by grinding any one of crystalline Forms A to U, in particular Form T. The present disclosure also provides methods for preparing crystalline forms, in particular Forms A, C, D, E, and I. Also disclosed herein are solid state forms of a compound of Formula (I) and methods of making the same. The present disclosure further provides methods of treating a disease mediated by MAT2A, for example, cancer, using the crystalline forms of the disclosure or a pharmaceutical composition thereof.
A layered microbead suitable for incorporating into a non-prescription consumable product is disclosed. The layered microbead may include a core and at least one active ingredient layer encapsulating the core. The active ingredient in the core can be different from the active ingredient in the encapsulating layer. The active ingredient in the core can be selected to counteract or enhance the effect of the active ingredient in the encapsulating layer. The layered microbead can further incorporate microspheres of active ingredient surrounded by polymer material. Method of manufacturing microspheres and microbeads are also described.
A system and method are provided for self-scheduling appointments via an electronic network. The user sends a scheduling request to a server and the authorisation of the user and/or the request is determined. Upon the receipt of an authorised request a database is accessed to identify a pre-authorised scheduling ticket for the user, the pre-authorised scheduling ticket including appointment scheduling information. An appointment proposal in accordance with the appointment scheduling information is provided to the user. Once a schedule has been accepted the information is included in the database. A set of rules can be applied to the appointment request to determine if the requested appointment is allowed. The set of rules can be hierarchical in nature.
All enrolled patients are included in the Clinical Cohort. Patients will complete assessments per standard of care through 2-year follow-up in Australia, Austria, Canada, France, Germany, Poland, Spain, Taiwan, Thailand, and the United States. Patients will complete assessments per standard of care through 5-year follow-up in China.
Complex coacervate core micelles as surface modification or surface treatment The present invention relates to devices carrying on the surface polymeric micelles and a process for the preparation thereof. It further relates to the use of polymeric micelles as a surface coating for rendering a surface anti-fouling and/or protein-resistant. The present invention relates to modified or treated surfaces carrying on polymeric micelles and a process for the preparation thereof. It further relates to the use of polymeric micelles as a surface coating for surface modification or surface treatment. The surface modification or surface treatment is for example for rendering a surface anti-fouling and/or protein-resistant, or for preventing bacteria proliferation, disinfecting, suppressing odours, preventing malodour, providing easy-cleaning or soil-release properties. These polymeric micelles are of the so-called complex coacervate core type, exhibiting a hydrophilic, neutral corona and a core, which is formed by charge complexation of oppositely charged blocks.
This project involves recruitment of 72 healthy males between the ages of 18 and 40 years. Forty eight of the participants will be regular cannabis users with a self-reported frequency of at least once weekly over the past 6 months, and a control group of twenty four cannabis non-users. Cannabis users will be asked to quit using cannabis for 11 weeks and will be required to attend 25 visits during the 11 week abstinence/contingency management period. Non-users will be asked to return to the clinic once a week for 11 weeks. Abstinence will be determined by self-report, qualitative urine rapid screening test at the clinic and quantitatively via Enzyme Immunoassay (EIA) analysis of THC (cannabinoids) and, by Liquid Chromatography Tandem Mass Spectrometry (LCMSMS) analysis of 11-nor-9-carboxy-∆ 9-tetrahydrocannabinol (THCCOOH) performed by an analytical lab contracted by the study team. Semen sample for both groups will be collected prior to the start of abstinence and after 11 weeks. Semen analysis and DNA methylation of sperm cells will be compared.
Left atrial (LA) blood flow plays an important role in diseases such as atrial fibrillation (AF) and atrial cardiomyopathy since alterations in the blood flow might lead to thrombus formation and stroke. Using traditional techniques, such as echocardiography, atrial flow velocities can be measured at the pulmonary veins and the mitral valve, but a comprehensive understanding of the three-dimensional atrial flow field is missing. Previously, ventricular flow has been analyzed using flow component analysis, revealing new insights into ventricular flow and function. Thus, the aim of this project was to develop a comprehensive flow component analysis method for the LA and explore its utility in 21 patients with paroxysmal atrial fibrillation compared with a control group of 8 participants. The flow field was derived from time-resolved CT acquired during sinus rhythm using computational fluid dynamics. Flow components were computed from particle tracking. We identified six atrial flow components: conduit, reservoir, delayed ejection, retained inflow, residual volume, and pulmonary vein backflow. It was shown that conduit flow, defined as blood entering and leaving the LA within the same diastolic phase, exists in most subjects. Although the volume of conduit and reservoir is similar in patients with paroxysmal AF in sinus rhythm and controls, the volume of the other components is increased in paroxysmal AF. Comprehensive quantification of LA flow using flow component analysis makes atrial blood flow quantifiable, thus facilitating investigation of mechanisms underlying atrial dysfunction and can increase understanding of atrial blood flow in disease progression and stroke risk.NEW & NOTEWORTHY We developed a new comprehensive approach to atrial blood component analysis that includes both conduit flow and residual volume and compared the flow components of atrial fibrillation (AF) patients in sinus rhythm with controls. Conduit and reservoir flow were similar between the groups, whereas components with longer residence time in the left atrium were increased in the AF group. This could add to the pathophysiological understanding of atrial diseases and possibly clinical management.
This invention relates to vector sequences that express growth inhibitory levels of essential genes used in combination with inhibitors that target the same gene. An example given is the use of the gene encoding the fatty acid biosynthesis enzyme enoyl-ACP reductase used in combination with the antimicrobial triclosan. The expression level of the enoyl-ACP reductase is sufficient to suppress the toxic effects of triclosan and the triclosan is used at levels that are sufficient to suppress the toxic effects of the enoyl-ACP reductase. The invention provides methods to enhance the growth and survival of genetically modified organisms and to increase the production and expression of plasmid vectors in the presence of triclosan, relative to methods that rely on antibiotics and antibiotic resistance markers. Also, the invention provides methods to limit the spread of genetically modified organisms. The vectors and methods are useful to avoid the use of antibiotics and antibiotic markers, to contain genetically modified organisms and to increase the production of recombinant material or metabolites from host organisms.
Procedure for obtaining alpha-alanil-2,6-dimethyl-aniline and beta-alanil-2,6-dimethyl-aniline. The synthesis of these derivatives is carried out in five steps. The first step consists of the protection of the amino group of alpha- or beta-alanine with ftalic anhydride to give the corresponding ftaloil-alanine. The second step consists of the formation of the acid chloride of the relevant ftaloil-alanine, which is carried out with a chloride of tionilo to reflux. Eliminating the excess of chloride is obtained the corresponding acid chloride. The third phase consists of the reaction of the corresponding chloride of ftaloyl-alanine with 2,6-dimethyl-aniline in a dioxane medium. A precipitate of ftaloil-alanil-2,6-dimetilanilin is obtained. The fourth phase of the process is the unlocking of the group used to protect the amino group from alanina in the first step and, finally, the last step consists in the formation of the corresponding alyan-2,6-dimethylaniline hydrochloride. (Machine-translation by Google Translate, not legally binding)
INTRODUCTION: Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) are structural disorders originating prenatally and present at birth. Affecting 4.2 to 1000 per 10,000 births globally, CAKUT includes conditions like posterior urethral valves, cloacal anomalies, and reflux nephropathy. These anomalies can lead to chronic kidney disease (CKD) or end-stage kidney disease (ESKD) in children, necessitating renal replacement therapy or transplantation.
OBJECTIVES: This article aims to provide an updated perspective on pediatric kidney transplantation for children with CAKUT, emphasizing pre-transplant evaluation and management to optimize long-term outcomes.
METHODS: A comprehensive urologic evaluation is essential for children with ESKD being considered for kidney transplantation. Key pre-transplant investigations include kidney/bladder ultrasound (US), voiding cystourethrogram (VCUG), uroflowmetry, and urodynamics (UDS)/video-urodynamics (VUDS). Non-operative interventions such as pharmacotherapy and clean intermittent catheterization (CIC) are also considered. Surgical interventions, like augmentation cystoplasty or continent catheterizable channels, are evaluated based on individual patient needs.
RESULTS: Kidney/bladder US and VCUG provide essential anatomical information. UDS offers comprehensive functional data, identifying hostile bladders needing pre-transplant optimization. Non-surgical measures like anticholinergics and CIC improve bladder function, while surgical options enhance compliance and capacity. Concurrent interventions during transplantation are feasible but require careful consideration of risks and benefits.
DISCUSSION: Children with CAKUT undergoing kidney transplantation exhibit comparable or better graft survival rates than those without CAKUT. However, those with lower urinary tract obstructions (LUTO) may have poorer long-term outcomes. UDS is crucial for evaluating bladder function pre-transplant, guiding the need for interventions. Long-term monitoring for urinary tract infections (UTIs) and bladder dysfunction is essential.
CONCLUSION: Optimal outcomes in pediatric kidney transplantation for CAKUT patients require thorough pre-transplant evaluation and management, particularly for those with LUTO. Multidisciplinary approaches ensure careful monitoring and timely interventions, improving graft survival and quality of life for these patients.
In the past decades, the therapeutic effect of glioblastoma (GBM) has not been significantly improved. Generous evidence indicates that S100A9 has a wide range of functions in tumors, but its exploration in GBM is less. The purpose of this study is to conduct a comprehensive bioinformatics analysis and cytological experiment on S100A9 in GBM. The expression data and clinical data of GBM samples were downloaded from the public database, and comprehensive bioinformatics analysis was performed on S100A9 in GBM using R software. Wound healing assay and transwell assay were used to detect the migration activity of cells, and colony formation assay, EdU staining, and CCK-8 assay were used to detect the proliferation activity of cells. The effect of S100A9 on the migration activity of M2 macrophages was verified by the cell co-culture method. The protein expression was detected by western blotting and immunohistochemical staining. S100A9 is an independent prognostic factor in GBM patients and is related to poor prognosis. It can be used as an effective tool to predict the response of GBM patients to immune checkpoint inhibitors (ICIs). In addition, S100A9 can promote the malignant progression of GBM and the migration of M2 macrophages. On the whole, our study highlights the potential value of S100A9 in predicting prognosis and immunotherapeutic response in GBM patients. More importantly, S100A9 may promote the malignant progress of GBM by involving in some carcinogenic pathways and remodeling the tumor microenvironment (TME).
A hypoglycemisant extract is obtained from edible mushrooms, preferably Psalliota campestris and Cantharellus cibarius, by a plurality of extractions using conventional extraction solvents such as methyl, ethyl or butyl alcohol, acetone, ether, water and chloroform.  An example describes preparing an aqueous pulp of mushrooms which is then extracted with alcohol, the extract admixed with acetone and filtered, the resultant liquid being further extracted with ether and the ether extract removed and a further extraction made on the remaining part.  The combined extracts are then concentrated by heating to 40-50 DEG  C. under vacuum and the resulting residue extracted with alcoholic ether at least twice. These extracts are concentrated as before and their residue extracted with aqueous alcohol to give the final product.  Other examples describe many variations of this process.  The extracts may be mixed with insulin or sulphamides and conventional substances to form compositions for internal and external use.
PURPOSE:The titled drug containing, quercitrin as an active constituent, and having the protecting action on hepatic disorder with low toxicity. CONSTITUTION:A protecting agent containing quercitrin expressed by the formula as an active constituent. The quercitrin is a compound having L-rhamnose linked to the hydroxyl group at the 3-position of the quercetin which is one of flavone derivatives. The effectiveness of the quercitrin is found by using the hepatic disorder model with acetaminophenone. The sleeping hours by pentobarbital and activities of glutamic oxalacetic transaminase (GOT) and glutamic  pyruvic transaminase (GPT) are used as indexes for knowing the degree of the hepatic disorder. The toxicity of the quercitrin is LD50>5,000mg and low. The  oral dose of the quercitrin as a protecting agent against the hepatic disorder is  within the range of 100-1,000mg/day, preferably 300-900mg/day.
PURPOSE: An oral antibacterial agent containing Syzygium samaragense or Syzygium aquaeum extract is provided to nature antibacterial activity which is specific to oral bacteria and to ensure safety. CONSTITUTION: An edible antibacterial agent contains Syzygium samaragense or Syzygium aquaeum extract. The extract is leaf extract of Syzygium samaragense or Syzygium aquaeum. The extract has activity to oral bacteria such as Porphyromonas gingivalis and Fusobacterium nucleatum. An oral composition contains the antibacterial agent having Syzygium samaragense or Syzygium aquaeum extract. The Syzygium samaragense or Syzygium aquaeum extract is obtained using water, methanol, ethanol, propanol, ether, chloroform, acetic acid ethyl, acetone, glycerin, and propylene glycol.
The influence of metabolic dysfunction-associated steatotic liver disease (MASLD) on gallbladder polyp development in both sexes remains elusive. Therefore, to clarify the role of MASLD in gallbladder polyp development, we investigated the longitudinal association between MASLD and gallbladder polyps. In this observational study, we included 5,527 gallbladder polyp-free patients who underwent > 2 health check-ups over > 2 years. Generalized estimation equations were used to analyze associations between MASLD and gallbladder polyp development according to repeated measures at baseline and the most recent stage. Gallbladder polyp development rates in men and women were 7.5% and 5.6% (p < 0.01), respectively. MASLD was not significantly correlated with gallbladder polyp development. Regarding the association between gallbladder polyp development (men: ≥6 mm and women: ≥5 mm) and the number of MASLD components following lifestyle habits, men and women with ≥ 4 MASLD components had odds ratios of 3.397 (95% confidence interval: 1.096-10.53) and 5.338 (1.054-27.04), respectively. Higher nonalcoholic fatty liver disease fibrosis scores were associated with significant risk of gallbladder polyp development in women (1.991, 1.047-3.785). Although MASLD influence on gallbladder polyp development differs by sex, close monitoring of patients with an increasing number of MASLD components is essential to prevent gallbladder polyp development. Specifically, men with ≥ 4 MASLD components should be monitored for gallbladder polyps measuring ≥ 6 mm.
Process comprises concentrating and desalting the culture filtrate from a culture soln. of Tendamistat producing microorganisms, and then either (a) mixing with 0-30 wt.% of a suitable organic solvent which is miscible with water, reducing the pH of this soln. to 3.2-5.5 or to 2-3 using an acid conventionally used in peptide chemistry and then raising the pH to 3.2-5.5 using a base, crystallising the tendamistat present in the soln. either by adding a seed crystal or by allowing the soln. to stand and then sepg. the crystals or (b) setting the pH to 1.0-3.0 using an acid conventional in peptide chemistry, opt. sepg. insol. impurities, mixing the soln. obtd. with salts conventionally used in the crystn. of proteins and then crystallising out the Tendamistat present in soln. either by adding a seed crystal or by allowing the soln. to stand and then sepg. the crystals.
TT-00420 tablets will be administered once daily in 21-day cycles. Dose escalation will be guided by a 3+3 design in Phase Ib to determine the recommended phase 2 dose (RP2D).
PURPOSE: To obtain a medicinal aerosol preparation containing no chlorofluorocarbons. CONSTITUTION: This medicinal aerosol preparation contains at least one medicinal active component, at least one surfactant and heptafluoropropane (R227) liquefied under pressure as a propellant. A compound having relatively higher polarity compared with R227 can be added. Suitable compounds are lower hydrocarbons such as propane, butane and pentane, aliphatic ethers such as dimethyl ether and aliphatic alcohols. It is preferable to use a monovalent alcohol having a low boiling point and high volatility. Ethanol and isopropanol are especially preferable. These compounds are added when a pressure should be reduced.
Attention-deficit/hyperactivity disorder (ADHD) commonly precedes the initial onset of mania in youth with familial risk for bipolar disorder (BD). Although ADHD youth with and without BD familial risk exhibit different clinical features, associated neuropathophysiological mechanisms remain poorly understood. This study aimed to identify brain functional network abnormalities associated with ADHD in youth with and without familial risk for BD. Resting-state functional magnetic resonance imaging scans were acquired from 37 ADHD youth with a family history of BD (high-risk), 45 ADHD youth without a family history of BD (low-risk), and 32 healthy controls (HC). Individual whole-brain functional networks were constructed, and graph theory analysis was applied to estimate network topological metrics. Topological metrics, including network efficiency, small-worldness and nodal centrality, were compared across groups, and associations between topological metrics and clinical ratings were evaluated. Compared to HC, low-risk ADHD youth exhibited weaker global integration (i.e., decreased global efficiency and increased characteristic path length), while high-risk ADHD youth showed a disruption of localized network components with decreased frontoparietal and frontolimbic connectivity. Common topological deficits were observed in the medial superior frontal gyrus between low- and high-risk ADHD. Distinct network deficits were found in the inferior parietal lobule and corticostriatal circuitry. Associations between global topological metrics and externalizing symptoms differed significantly between the two ADHD groups. Different patterns of functional network topological abnormalities were found in high- as compared to low-risk ADHD, suggesting that ADHD in youth with BD familial risk may represent a phenotype that is different from ADHD alone.
Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.